Academic Journal
Safety, tolerability, and pharmacokinetics of fluoropezil (DC20), a novel acetylcholinesterase inhibitor: A phase I study in healthy young and elderly Chinese subjects.
| Title: | Safety, tolerability, and pharmacokinetics of fluoropezil (DC20), a novel acetylcholinesterase inhibitor: A phase I study in healthy young and elderly Chinese subjects. |
|---|---|
| Authors: | Qian H; Drug Clinical Trial Center, Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.; Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, China., Yu C; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China., Zhu H; Drug Clinical Trial Center, Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.; Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, China., Ding Q; Drug Clinical Trial Center, Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.; Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, China., Cai Y; Drug Clinical Trial Center, Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.; Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, China., Jing J; Jiangsu Kanion Pharmaceutical Co., Ltd, Lianyungang, China., Xu X; Shanghai Kerlin Biomedical Technology Co., Ltd, Shanghai, China., Guo R; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China., Zhang H; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China., Liu H; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China., Chen X; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China., Liu Y; Drug Clinical Trial Center, Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.; Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, China. |
| Source: | Clinical and translational science [Clin Transl Sci] 2023 May; Vol. 16 (5), pp. 810-822. Date of Electronic Publication: 2023 Feb 26. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1752-8062 (Electronic) Linking ISSN: 17528054 NLM ISO Abbreviation: Clin Transl Sci Subsets: MEDLINE |
| Database: | MEDLINE Complete |
| Full text is not displayed to guests. | Login for full access. |
Accede al texto completo | ResultId |
1 |
|---|---|
| Header |
mdc MEDLINE Complete 36798012 2 Academic Journal academicJournal |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=mdc&AN=36798012 |
| FullText |
Array
(
[0] => Array
(
[Type] => pdflink
)
)
Array ( [Availability] => 1 ) Array ( [0] => Array ( [Url] => https://resolver.ebscohost.com/openurl?authtype=cookie,ip,url,guest&custid=ns017177&groupid=main&profile=ftf&sid=EBSCO:mdc&genre=article&issn=17528062&ISBN=&volume=16&issue=5&date=20230501&spage=810&pages=810-822&title=Clinical and translational science&atitle=Safety%2C%20tolerability%2C%20and%20pharmacokinetics%20of%20fluoropezil%20%28DC20%29%2C%20a%20novel%20acetylcholinesterase%20inhibitor%3A%20A%20phase%20I%20study%20in%20healthy%20young%20and%20elderly%20Chinese%20subjects.&aulast=Qian%20H&id=DOI:10.1111/cts.13490 [Name] => Full Text Finder (ns017177) [Category] => fullText [Text] => Accede al texto completo [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Safety, tolerability, and pharmacokinetics of fluoropezil (DC20), a novel acetylcholinesterase inhibitor: A phase I study in healthy young and elderly Chinese subjects.
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AU" term="%22Qian+H%22">Qian H</searchLink>; Drug Clinical Trial Center, Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.; Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Yu+C%22">Yu C</searchLink>; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Zhu+H%22">Zhu H</searchLink>; Drug Clinical Trial Center, Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.; Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Ding+Q%22">Ding Q</searchLink>; Drug Clinical Trial Center, Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.; Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Cai+Y%22">Cai Y</searchLink>; Drug Clinical Trial Center, Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.; Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Jing+J%22">Jing J</searchLink>; Jiangsu Kanion Pharmaceutical Co., Ltd, Lianyungang, China.<br /><searchLink fieldCode="AU" term="%22Xu+X%22">Xu X</searchLink>; Shanghai Kerlin Biomedical Technology Co., Ltd, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Guo+R%22">Guo R</searchLink>; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Zhang+H%22">Zhang H</searchLink>; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Liu+H%22">Liu H</searchLink>; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Chen+X%22">Chen X</searchLink>; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Liu+Y%22">Liu Y</searchLink>; Drug Clinical Trial Center, Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.; Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, China. ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => <searchLink fieldCode="JN" term="%22101474067%22">Clinical and translational science</searchLink> [Clin Transl Sci] 2023 May; Vol. 16 (5), pp. 810-822. <i>Date of Electronic Publication: </i>2023 Feb 26. ) Array ( [Name] => TypePub [Label] => Publication Type [Group] => TypPub [Data] => Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't ) Array ( [Name] => TitleSource [Label] => Journal Info [Group] => Src [Data] => <i>Publisher: </i><searchLink fieldCode="PB" term="%22WileyBlackwell+Pub%22">WileyBlackwell Pub </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101474067 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1752-8062 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2217528054%22">17528054 </searchLink><i>NLM ISO Abbreviation: </i>Clin Transl Sci <i>Subsets: </i>MEDLINE ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1111/cts.13490
)
)
[Languages] => Array
(
[0] => Array
(
[Code] => eng
[Text] => English
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[StartPage] => 810
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Safety, tolerability, and pharmacokinetics of fluoropezil (DC20), a novel acetylcholinesterase inhibitor: A phase I study in healthy young and elderly Chinese subjects.
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Qian H
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Yu C
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Zhu H
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ding Q
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Cai Y
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Jing J
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Xu X
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Guo R
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Zhang H
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Liu H
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Chen X
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Liu Y
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 05
[Text] => 2023 May
[Type] => published
[Y] => 2023
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-electronic
[Value] => 1752-8062
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 16
)
[1] => Array
(
[Type] => issue
[Value] => 5
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Clinical and translational science
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |